Stock Taper
SCREENER COMPARE ANY 2 STOCKS
PYXS
PYXIS ONCOLOGY, INC.
NASDAQ
$3.08
▼ DOWN 1.28% (-0.04)

KEY STATISTICS

Market Cap$195.13 M
52w High$5.55
52w Low$1.03
Dividend Yield—
Frequency—
P/E-2.18
Volume682.27K
Shares Out.63.36M

COMPANY

LEADERSHIP

Thomas Civik
CHIEF EXECUTIVE
Thomas Civik

COMPENSATION 2026

Salary$646,875
Stock Awards$0
Incentive Plan Pay$291,094
All Other Comp.$10,500
Total$1,671,545

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 8, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
56

PRICE TARGET

Target High$7.00
Target Low$6.00
Target Median$6.50
Target Consensus$6.50

UPCOMING EARNINGS

DateNov 2, 2026
DayMonday
Rev. Est.—
NOV
2
MON

PRICE

$3.08 ▼ DOWN 1.28% (−$0.04)
$3.05$3.10$3.159:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM3.08

About Pyxis Oncology, Inc.

https://www.pyxisoncology.com ↗

Pyxis Oncology, Inc. is a preclinical biopharmaceutical company developing immuno-oncology therapies and antibody drug conjugates for various solid tumors and hematologic cancers.

INDUSTRY

Biotechnology

A PRODUCT PYXIS ONCOLOGY, INC. IS KNOWN FOR

Micvotabart pelidotin (MICVO, formerly PYX-201)
Micvotabart pelidotin (MICVO, formerly PYX-201)

Micvotabart pelidotin is Pyxis Oncology’s lead Phase 1 ADC targeting tumor extracellular matrix proteins to treat solid tumors, especially recurrent/metastatic head and neck squamous cell carcinoma.

COMPETITORS

COMPETITOR
ABBV COMPARE
ADCT COMPARE
AZN COMPARE
BMY COMPARE
GILD COMPARE

Revenue by Products

IconPRODUCTQ2-2024Q3-2024Q3-2025Q4-2025
Royalty$8.15M $8.15M — —
Milestone Revenue— — $2.82M $0 ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
22
LISTED HERE
5
RANKED BY POSITION SIZE
VTS.AX
0.00% · 1.6M
IBB
0.01% · 394.3K
DFMC
0.00% · 10.3K
IBBQ
0.01% · 3.7K
BIB
0.01% · 2.2K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
41.11%
HOLDERS
108
TOP 12 OF 108 · RANKED BY POSITION SIZE
Pfizer Inc
7.0M sh · $9.21M
Laurion Capital Management LP
5.0M sh · $7.3M
Blackrock Inc.
2.8M sh · $9.22M
Tang Capital Management LLC
2.5M sh · $5.55M
Vanguard Group Inc
2.3M sh · $2.69M
Perceptive Advisors LLC
1.2M sh · $2.62M
Palo Alto Investors LP
1.0M sh · $1.19M
683 Capital Management, LLC
896.3K sh · $1.31M
Renaissance Technologies LLC
888.7K sh · $1.3M
Millennium Management LLC
815.3K sh · $1.81M
Blackrock, Inc.
788.8K sh · $1.15M
Jane Street Group, LLC
786.0K sh · $903.91K

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
DIRECTOR
Dupont Jakob
Purchase · 46.0K shares
2026-08-20
★
DIRECTOR, OFFICER: INTERIM CEO
Civik Thomas
Purchase · 251.0K shares
2026-08-12
★
10 PERCENT OWNER
GordonMD Global Investments LP
— · —
2026-06-30
★
10 PERCENT OWNER
GordonMD Global Investments LP
— · 4.9M shares
2026-06-30

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
OUTPERFORM 2
OVERWEIGHT 1
6 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY Leerink Partners OUTPERFORM Stifel BUY RBC Capital OUTPERFORM Stephens & Co. OVERWEIGHT Guggenheim BUY

SECTORS PEERS

PEERPRICE
ZURA$5.85COMPARE
AVIR$5.43COMPARE
FHTX$7.07COMPARE
ENTA$13.47COMPARE
VYGR$3.39COMPARE
IMRX$5.30COMPARE
CRBU$1.66COMPARE
TNYA$0.70COMPARE